The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic in...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/335d5896954c4b0ea9323a843dc2c1dd |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|